Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $217,597 | $101,788 | $165,007 | $114,091 |
| Short-Term Investments | $0 | $223,128 | $178,019 | $84,096 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $382,199 | $10,353 | $11,480 | $7,164 |
| Total Curr. Assets | $599,796 | $335,269 | $354,506 | $205,351 |
| Property Plant & Equip (Net) | $7 | $22 | $38 | $53 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $144 | $433 | $397 | $499 |
| Total NC Assets | $151 | $455 | $435 | $552 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $599,947 | $335,724 | $354,941 | $205,903 |
| Liabilities | – | – | – | – |
| Payables | $1,121 | $3,164 | $373 | $479 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $22,399 | $2,623 | $1,150 | $3,582 |
| Total Curr. Liab. | $23,520 | $22,173 | $13,386 | $14,646 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $23,520 | $22,173 | $13,386 | $14,646 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $8 | $6 | $6 | $5 |
| Retained Earnings | -$424,935 | -$388,003 | -$344,729 | -$302,518 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,001,354 | $0 | $0 | $0 |
| Total Equity | $576,427 | $313,551 | $341,555 | $191,257 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $599,947 | $335,724 | $354,941 | $205,903 |
| Net Debt | -$217,597 | -$101,788 | -$165,007 | -$114,091 |